Abstract-Pre␤1-high density lipoprotein (pre␤1-HDL), the initial acceptor of cell-derived cholesterol, can be generated from HDL 2 by hepatic lipase. Because bezafibrate elevates lipase activity, it may increase pre␤1-HDL at the expense of HDL 2 . To answer this question, we determined the apolipoprotein A-I (apoA-I) distribution in 20 hypertriglyceridemics (triglyceridesϾ2.26 mmol/L) and 20 sex-matched normolipidemics by native 2-dimensional gel electrophoresis. At baseline, pre␤1-HDL was 70% higher in hypertriglyceridemics than in normolipidemics (123.5Ϯ49. 
arlier studies have shown that HDL consists of several distinct subfractions with different compositions and functions. [1] [2] [3] [4] [5] [6] In experiments with fibroblasts or HepG2 cells, cell-derived free cholesterol rapidly moves to the minor HDL subfraction, pre␤1-HDL. [1] [2] [3] [4] [5] This free cholesterol in pre␤1-HDL is subsequently transferred to pre-␤3-HDL 2,4,5 and is then esterified by lecithin:cholesterol acyltransferase (LCAT). 2 Although the origin of pre␤1-HDL has not been fully elucidated, pre␤1-HDL is probably generated during the conversion of ␣-migrating HDL. [7] [8] [9] [10] Moreover, pre␤1-HDL may be secreted directly from the liver 5 or formed by the interaction of free apoA-I with certain types of cells. 11 In in vitro experiments, pre␤1-HDL was generated from triglyceride (TG)-enriched HDL 2 by hepatic lipase. 7, 8 Bezafibrate is 1 of the fibric acid derivatives widely used to treat patients with hypertriglyceridemia (HTG) and combined hyperlipidemia. [12] [13] [14] Because bezafibrate increases lipase activity, [15] [16] [17] it is highly possible that bezafibrate promotes conversion of HDL 2 to pre␤1-HDL. To ascertain whether bezafibrate increases pre␤1-HDL at the expense of HDL 2 in HTG, we determined the HDL subfraction concentration before and after bezafibrate treatment in 20 patients with HTG by native 2-dimensional gel electrophoresis. We also carried out in vitro experiments with TG lipase to generate pre␤1-HDL from HDL 2 or plasma.
Methods

Patient Selection
Patients with at least 2 fasting TG concentrations Ն2.26 mmol/L (200 mg/dL) were recruited. None took medication for the preceding 3 months. We excluded regular drinkers with an ethanol intake Ͼ25 g/d and patients with severe liver disease, renal disease, thyroid disease, diabetes mellitus, coronary artery disease, cerebrovascular disease, or other significant systemic illness. Twenty patients with HTG (HTG group; 18 men and 2 women) were enrolled in this study. We also examined 20 sex-matched healthy volunteers [control group; total cholesterol (TC) Ͻ6.47 mmol/L (250 mg/dL) and TGϽ2.26 mmol/L (200 mg/dL)]. After explaining the purpose of this study, we obtained informed consent from each participant. The study protocol was approved by the ethics committee of our institution.
Study Design
The baseline data described below were obtained in both groups. In the HTG group, additional data were obtained after a 4-week bezafibrate treatment (400 mg/d). All of the patients maintained their usual diet, smoking habits, and level of physical activity throughout the study period.
For lipoprotein analysis, blood was drawn into an ice-chilled glass tube supplemented with K 2 -EDTA after an overnight fast. 10,18 -22 Plasma was obtained by centrifugation at 0°C, 2000g for 30 minutes. To analyze cholesteryl ester transfer protein (CETP) mass, an aliquot of plasma was stored at Ϫ80°C. To analyze lipase activity, postheparin plasma was obtained as described below.
Lipoprotein Analyses
The TC, TG, and phospholipid (PL) concentrations were measured enzymatically on a Hitachi 7450 analyzer (Hitachi). The HDL cholesterol (HDL-C) concentration was determined by a homogeneous method (Determiner L HDL, Kyowa Medex) on the same analyzer. The apolipoprotein A-I (apoA-I) concentration was measured by turbidimetric immunoassay (Apo A-I Auto · N "Daiichi," Daiichi Pure Chemicals) on a Hitachi 7170 analyzer. In the apoA-I measurement, the coefficient of variation in the same assay was Ͻ1%, and that between assays was Ͻ2%.
HDL Fractionation
In all subjects, HDL was fractionated by native 2-dimensional gel electrophoresis as described previously. 3,10,18 -22 Fresh plasma was run on an agarose gel (0.75%) and then on a 2% to 15% polyacrylamide gel at 0°C at 100 V for 20 hours. Fractionated HDL was electroblotted to a nitrocellulose sheet at 0°C and detected by goat anti-human apoA-I antibodies (Daiichi Pure Chemicals) iodinated with Na 125 I (NEN) by a modification of the chloramine T method. 23 The relative concentration was expressed as the percent apoA-I based on the radioactivity of each subfraction. 3,10,18 -22 The absolute concentration was calculated from the percent apoA-I and the plasma apoA-I concentration.
The molecular size of pre␤1-HDL was determined by using a 4% to 30% polyacrylamide gel run to equilibrium. 1 After plasma was separated on a 0.75% agarose gel, the pre-␤ position was cut from the gel. The agarose gel pieces were placed on a 4% to 30% gradient polyacrylamide gel together with the molecular-weight standards (high-molecular-weight electrophoresis calibration kit, Amersham Pharmacia Biotech) supplemented with ovalbumin (Sigma). The gradient gel was electrophoresed at 0°C, 200 V for 24 hours. Fractionated pre␤1-HDL was electroblotted to a nitrocellulose sheet and detected as described above. The molecular-weight standards transferred to a nitrocellulose sheet were stained with amido black solution (Sigma).
In some subjects, HDL 2 (1.063ϽdϽ1.125) and HDL 3 (1.125ϽdϽ1.210) were separated by sequential ultracentrifugation according to the method of Havel et al. 24 The lipid concentrations in the separated fractions were determined by the enzymatic method on a Hitachi 7450 analyzer.
Lipase Assay
In the HTG group, lipase activity was assayed in postheparin plasma before and after bezafibrate treatment. Ten minutes after heparin injection (50 U/kg), blood was obtained from a brachial vein and mixed well with sodium citrate (final concentration, 0.38%, wt/vol) in an ice-cooled glass tube. The plasma was separated by centrifugation at 0°C and stored at Ϫ80°C until measurement. Triton X-100 -stabilized triolein substrate was mixed with postheparin plasma (10/1, vol/vol) and incubated at 37°C during the hydrolysis reaction. 25 The reaction was stopped by placing the tubes in ice. The mixture was extracted with organic solvents. The free fatty acids released during the incubation were measured by a calorimetric method. Hepatic lipase activity was selectively measured by inhibiting lipoprotein lipase with 1 mol/L NaCl. Lipoprotein lipase activity was determined by subtracting hepatic lipase activity from the total lipase activity. The lipase activity was expressed as the amount of free fatty acids released per minute (mmol · L -1 · min -1 ).
Incubation Experiment
We examined the effect of lipase on HDL 2 and plasma in vitro. (3700 U/L) in the same way. The distribution of apoA-I was determined by 2-dimensional gel electrophoresis. In the experiment with HDL 2 , the changes in its size and composition were also determined by gel filtration chromatography described below.
Gel Filtration Chromatography
Either the hydrolyzed or unhydrolyzed sample was applied to a fast protein liquid chromatography system equipped with a Superose 6 column (1ϫ30 cm, Amersham Pharmacia Biotech). The lipoproteins were eluted at 0.5 mL/min with PBS containing 1 mmol/L EDTA (pH 7.4). Lipids and apoA-I concentrations in the separated fractions were determined on a Hitachi 7450 analyzer.
Other Assays
LCAT activity was measured by the endogenous substrate method described by Nagasaki and Akanuma. 26 The immunoreactive CETP mass was determined by enzyme-linked immunoassay (CETP Chugai ELISE, Chugai Pharmaceutical).
Statistical Analysis
Paired t tests were used to analyze the changes in concentration or activity induced by bezafibrate. The influence of bezafibrate was considered significant at PϽ0.05.
Results
Effect of Bezafibrate on Lipoprotein Concentration, CETP Mass, and LCAT Activity
At baseline, both TC and TG were significantly higher in the HTG group (6.62Ϯ1. 29 
Effect of Bezafibrate on HDL Subfractions
Native 2-dimensional gel electrophoresis revealed that pre␤1-HDL spots were larger in the HTG group than in the control group, whereas the HDL 2b spot was smaller in the HTG group than in the control group ( Figures 1A and 1C) . Quantification of the HDL subfractions confirmed this observation ( Table 1 ). The baseline level of pre␤1-HDL in the HTG group was 70% higher than that in the control group. When we combined the 2 groups, the pre␤1-HDL concentration was positively correlated with the TG concentration (rϭ0.634, PϽ0.001; Figure I ; please see http:// atvb.ahajournals.org) but not with the apoA-I (rϭ0.163) or HDL-C (rϭ0.016) concentration or BMI (rϭ0.006).
After 4 weeks of bezafibrate treatment, the pre␤1-HDL increased by 30% from baseline ( Figures 1A and 1B and Table 1 ). The posttreatment level of pre␤1-HDL was more than double that in the control group. Of the 6 HDL subfractions, HDL 2b was the only subfraction that decreased significantly after bezafibrate treatment ( Figures 1A and 1B and Table 1 ).
Ultracentrifugal analysis revealed that bezafibrate markedly reduced the TG content in HDL particles. At baseline, TG concentrations in HDL 2 and HDL 3 were much higher in the HTG group than in the control group (Table 2) . After 4 weeks of treatment, TG concentration decreased by 46% in HDL 2 and by 36% in HDL 3 . On the contrary, TC concentrations increased in both HDL 2 and HDL 3 . The PL-to-TC ratio decreased significantly in HDL 2 .
Molecular Weight of Pre␤1-HDL
According to the mobility on the 4% to 30% polyacrylamide gel run to equilibrium, the molecular weight of pre␤1-HDL was 67 and 60 kDa in both control and HTG plasma ( Figure  II ; please see http://atvb.ahajournals.org). The molecular size of pre␤1-HDL did not change after bezafibrate treatment (data not shown).
Effect of Bezafibrate on Lipase Activity
After 4 weeks of bezafibrate treatment, the mean lipoprotein lipase activity increased from 0.386Ϯ0.087 to 0.502Ϯ0.075 mmol · L -1 · min -1 (PϽ0.005, nϭ10), and the mean hepatic lipase activity increased from 0.241Ϯ0.077 to 0.300Ϯ0.078 mmol · L -1 · min -1 (PϽ0.005, nϭ10). However, the changes in lipase activity were not correlated significantly with those in pre␤1-HDL (data not shown).
Effect of TG Lipase on Isolated HDL 2
TG lipase clearly promoted the conversion of HDL 2 to pre␤1-HDL. When HDL 2 was incubated with TG lipase, pre␤1-HDL appeared at 30 minutes, and the size of HDL 2 was significantly reduced (Figure 2 ). Gel filtration chromatography revealed that HDL 2 lost not only TG but also PL and apoA-I after incubation with TG lipase (Figures 3A and 3B) . On the contrary, the TC content in HDL 2 did not change during incubation (data not shown). It is apparent that the second apoA-I peak appeared after incubation with TG lipase ( Figure 3B) .
When plasma was incubated with TG lipase, pre␤1-HDL increased as a function of time. On the other hand, HDL 2b and HDL 2a decreased in this order (Figure 4 ). When we incubated the plasma for a longer time or with an excess amount of TG lipase, however, pre␤1-HDL decreased, and smaller pre␤-migrating particles increased (data not shown).
Discussion
This study indicates that bezafibrate increases pre␤1-HDL at the expense of HDL 2 in HTG. We found that pre␤1-HDL increased by 30% and that HDL 2b decreased by 32% after 4 weeks of bezafibrate treatment ( Table 1 ). The percent increase in pre␤1-HDL (30%) was about 4 times greater than that in apoA-I (8%). Bezafibrate probably promotes the conversion of HDL 2 to pre␤1-HDL by increasing hepatic lipase activity. In this study, hepatic lipase activity increased by 24%. Because the HDL 2 of HTG patients is rich in TG (Table 2) , 27 their HDL 2 must be efficiently hydrolyzed by hepatic lipase. Barrans et al 7 showed that pre␤1-HDL was generated from human TG-enriched HDL 2 after a 120-minute incubation with rat hepatic lipase. The remaining HDL 2 lost not only TG but also PL and apoA-I. 8 Because PL and apoA-I are major constituents of pre␤1-HDL, 1 pre␤1-HDL is probably dissociated from the surface of HDL 2 . In our experiment with HDL 2 , pre␤1-HDL was generated after incubation with TG lipase (Figure 2 ). Gel filtration chromatography confirmed that the hydrolyzed HDL 2 lost TG, PL, and apoA-I (Figure 3) . Although the second apoA-I peak did not contain a significant amount of PL, the sample dilution probably caused the dissociation of PL and apoA-I of pre␤1-HDL. 10, 28 In a similar experiment with plasma, pre␤1-HDL increased linearly during incubation with TG lipase (Figure 4) . Interestingly, it was predominantly HDL 2b that decreased during the first 30 minutes, whereas HDL 2a decreased thereafter. Thus, pre␤1-HDL is probably generated from HDL 2b in vivo, because HDL passes through the liver (the location of hepatic lipase) quickly. This hypothesis is consistent with the changes in HDL subfractions induced by bezafibrate ( Figures 1A and 1B and Table 1) .
We failed to find a positive correlation between the change in pre␤1-HDL and that in hepatic lipase activity in the HTG group, probably because bezafibrate alters other factors known to regulate HDL metabolism. First, bezafibrate binds to the peroxisome proliferater-activated receptor-␣ (PPAR-␣) and enhances apoA-I synthesis.
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Pre␤1-HDL was detected in lipoproteins newly secreted from HepG2 cells. 5 These data suggest that increased apoA-I synthesis may directly contribute to the increase in pre␤1-HDL concentration. Second, bezafibrate decreases TG-rich lipoproteins markedly. [12] [13] [14] Thus, the net TG transfer between TG-rich lipoproteins and HDL 2 must decrease. 30 In the HTG group, the TG content of HDL 2 was lower after bezafibrate treatment than at baseline (Table  2) . Such HDL 2 is likely to be less susceptible to hepatic lipase. In addition, bezafibrate decreased the LDL-C and CETP mass, which was positively correlated with the Figure 2 . Generation of pre␤1-HDL from ultracentrifugally isolated HDL 2 by TG lipase. HDL 2 was incubated at 37°C for 10 minutes with TG lipase (7200 U/L) in the presence of 5% human serum albumin. HDL subfractions were separated by nondenaturing 2-dimensional gel electrophoresis, and the apoA-I distribution was determined as described in Methods pre␤1-HDL concentration. 21, 22 These changes induced by bezafibrate may reduce the pre␤1-HDL concentration. Therefore, it is reasonable to conclude that the overall effect of bezafibrate on pre␤1-HDL concentration is not simply dependent on changes in hepatic lipase activity.
Bezafibrate is expected to increase cell-to-plasma cholesterol transport in the HTG group by the following mechanisms. First, bezafibrate increases pre␤1-HDL (Figure 1 and Table 1 ) which is the initial acceptor of cell-derived cholesterol. [1] [2] [3] [4] [5] In cultured fibroblasts, cell-toplasma cholesterol efflux is proportional to pre␤1-HDL concentration. 31 Second, bezafibrate decreases VLDL, 27 which impairs cell-to-plasma cholesterol efflux. 32 In patients with non-insulin dependent diabetes mellitus, cholesterol efflux was lower than that in normolipidemic subjects. 32, 33 This tendency was prominent in the postprandial state. 33 When VLDL was removed from plasma by an apoE immunoaffinity column, cholesterol efflux was normalized. 32 These results strongly suggest that impaired cholesterol efflux in diabetic patients is related to the increased plasma-to-cell cholesterol influx due to increased VLDL. Therefore, cell-to-plasma cholesterol transport is probably reduced at baseline in the HTG group, although the baseline pre␤1-HDL concentration was higher in the HTG group than in the control group.
Recent clinical trials have shown that bezafibrate is equally effective in preventing coronary events in survivors of myocardial infarction as are other cholesterollowering drugs, although it does not have as great a cholesterol-lowering effect. 13, 14 This preventive effect of bezafibrate may be due to the reduction in TG-rich lipoproteins (including remnant lipoproteins), fibrinogen, or enhanced conversion of HDL. More study is needed to clarify whether the bezafibrate-induced increase in pre␤1-HDL is antiatherogenic. In summary, bezafibrate increases pre␤1-HDL at the expense of HDL 2 in HTG. We speculate that such changes in the HDL subfractions may favor reverse cholesterol transport.
